Introduction
============

Leukemia, a blood or bone marrow cancer, is the seventh most common cancer in humans of all ages with the highest incidence among children aged 14 years or less.[@b1-ijn-10-1649] In the United States, an estimated 48,610 new leukemia cases with 23,620 deaths were reported in 2013. Among these fatalities were children, comprising 30% of the cases.[@b2-ijn-10-1649]

There have been dramatic improvements in blood cancer treatment using chemotherapy, ionizing radiation, radioimmunotherapy, immunotherapy, gene therapy, and stem cell transplantation. However, most of these therapies are plagued with side effects, and almost all cause cytotoxicity in healthy cells.[@b3-ijn-10-1649]

Natural compounds have been an important source of drugs since ancient times. In medicine, some natural compounds were initially used as therapeutic compounds while others served as sources of chemical templates for the development of synthetic drugs. Many active principles derived from natural compounds have powerful chemopreventive activities in diseases.[@b4-ijn-10-1649] Active principles from natural sources with anticancer properties exhibit their activities via apoptotic and cell-signaling pathways, and act on cancer targets. These activities suggest that compounds derived from natural compounds are excellent starting points for the design and development of novel and biologically active cancer preventive agents.[@b5-ijn-10-1649]

Although natural products have strong therapeutic values, many of their derivatives have poor water solubility and bioavailability, which severely limit their use in medicine.[@b6-ijn-10-1649] The nanoparticle delivery systems are newly introduced methods to overcome these limitations, turning potential but poorly soluble drugs into effective therapeutic agents.[@b7-ijn-10-1649] Among the nanoparticles, lipid nanoparticles are particularly compatible for use in humans and animals. These nanoparticles are not only less toxic to normal cells and biodegradable even with loaded drugs but they have also been recognized as safe and effective for topical and parenteral applications.[@b8-ijn-10-1649] Natural product nanoparticles with anticancer properties offer considerable advantage over currently employed chemopreventive and chemotherapeutic approaches in the treatment of cancers.[@b4-ijn-10-1649]

Nanocarriers are nanosized materials (1--100 nm) that can carry multiple drugs or compounds. Nanocarriers can also be used to increase local drug concentration by the incorporation of drugs while facilitating controlled release at the targets. Currently, there are only a few clinically approved nanocarriers that incorporate molecules for selective binding and targeting of cancer cells, which comprise polymer conjugates, polymeric nanoparticles, lipid-based carriers (liposomes and micelles), dendrimers, carbon nanotubes, and gold nanoparticles (nanoshells and nanocages).[@b9-ijn-10-1649]

Zerumbone (ZER), the predominant natural compound in the rhizome of *Zingiber zerumbet*, has poor water solubility. We have developed a ZER-loaded nanostructured lipid carrier (NLC) (ZER-NLC) by the high-pressure homogenization technique. ZER-NLC was shown to have anticancer properties and is particularly effective in the treatment of a human lymphoblastic leukemia cell line. Physicochemical and stability characterization showed that ZER-NLC possesses all the characteristics of an excellent delivery system for ZER.[@b10-ijn-10-1649],[@b11-ijn-10-1649]

Although ZER-NLC was shown to exhibit antileukemia properties in vitro, its in vivo effect was uncertain. Thus, the present study was conducted to determine the effect of ZER-NLC on WEHI-3B (murine myelomonocytic leukemia) cell-induced leukemia in a BALB/c mice model. The murine system was chosen because of ease of establishment of leukemia in this animal model.[@b12-ijn-10-1649]

Materials and methods
=====================

Leukemia cell line and culture condition
----------------------------------------

The murine myelocytic leukemia cell line (WEHI-3B) was purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were maintained in a complete growing RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) medium, supplemented with 10% fetal bovine serum (FBS) (PAA, Linz, Austria), and 1% antibiotic-antimycotic (Thermo Fisher Scientific, Waltham, MA, USA) in 75 cm^2^ culture flasks (TPP, Trasadingen, Switzerland) at 37°C and 5% CO~2~ in a humidified incubator (Binder, Tuttingen, Germany).

Reagents and chemicals
----------------------

All reagents and chemicals were analytical grade and obtained from highly reputed companies. 3-\[4,5-Dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide (MTT) dye, dimethylsulfoxide (DMSO), doxorubicin, Hoechst 33342, propidium iodide (PI), phosphate-buffered saline (PBS) tablets, bovine serum albumin (BSA), ethylenediaminetetraacetic acid (EDTA), Triton X-100, RNAase A, Bradford stain, protease inhibitor cocktail, Tween-20, sodium dodecyl sulfate (SDS), formaldehyde, 4% glutaraldehyde, sodium cocodylate, osmium tetra-oxide, uranyl acetate, citrate, and skimmed milk powder were purchased from Sigma-Aldrich. Other reagents and chemicals used were 10% formalin (Triangle Biomedicinal Sciences (TBS), Cincinnati, OH, USA), paraffin wax (Leica EG1160, Germany), ketamine·HCl (Ilium, Ketamil, Australia) xylazine (Ilium, Xylazil-20, Australia), toulidine blue (Thermo Fisher Scientific), resin (TAAB Company, England), and RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA).

ZER-loaded NLC
--------------

Pure (99.96%) colorless ZER crystals were extracted from the essential oil of fresh *Zingiber zerumbet* rhizomes by steam distillation according to the method described earlier.[@b10-ijn-10-1649] ZER-NLC was prepared by a high-pressure homogenization method and characterized by zetasizer, reverse-phase high-performance liquid chromatography, transmission electron microscopy, wide-angle X-ray diffraction, differential scanning colorimetry, and Franz Diffusion Cell system analyses. The loaded nanoparticles were shown to be physically stable with a particle size of 52.68±0.1 nm, zeta potential of −25.03±1.24 mV, and polydipersity index of 0.29±0.0041 μm.[@b10-ijn-10-1649],[@b11-ijn-10-1649]

In vitro cytotoxic effect of ZER-loaded NLC on WEHI-3B
------------------------------------------------------

### Colorimetric cytotoxicity effect of ZER-NLC on WEHI-3B cells

The antiproliferative effect of ZER-NLC at concentrations of 1--100 μg/mL on treated WEHI-3B cells was assessed using MTT assay according to the method described earlier.[@b13-ijn-10-1649] Briefly, about 1×10^5^ cells were seeded into each well of a 96-well plate and incubated for 24 hours to allow attachment. After treating with ZER-NLC for 24 hours, 48 hours, and 72 hours, MTT was freshly prepared at a concentration of 5.5 mg/mL and incubated with cells for 4 hours. The formazan crystals formed were dissolved in 100 μL of DMSO. The optical density (OD) of the suspension was measured at 570 nm using an ELISA plate reader (Universal Microplate reader; Biotech, Inc., Oklahoma City, OK, USA). Doxorubicin treatment was used as positive control, while DMSO (0.1%) was used as negative control. Finally, the IC~50~ (half maximal inhibitory concentration) values were compared with those of the positive antineoplastic agent control. All experiments were conducted in triplicates.

### Morphological assessment of apoptotic cells by fluorescent microscopy

WEHI-3B cells (1×10^5^ cells/mL) were seeded on a 25 cm^2^ culture flask and treated with 7.5±0.55 μg/mL (IC~50~ concentration at 72 hours) of ZER-NLC for 24 hours, 48 hours, and 72 hours. The cells were then collected and washed twice with cold PBS. Approximately 10 μL of cell suspension were stained on a glass slide, in the dark, with a mixture of 10 μL Hoechst 33342 (1 mM) and 5 μL PI (100 μg/mL). Morphological changes of stained cells were observed under a fluorescence microscope (Zeiss, Germany) within 30 minutes of preparation.[@b14-ijn-10-1649]

### Early cell apoptosis detection by annexin V-FITC/PI assay

Apoptosis was detected with an annexin V/FITC kit (Sigma-Aldrich) following instructions of the manufacturer without modifications. Briefly, about 1×10^5^ WEHI-3B cells pretreated for 12 hours, 24 hours, and 48 hours with ZER-NLC were harvested and washed with prechilled PBS. The cells were suspended in 500 μL of 1× binding buffer and stained with annexin V (5 μL) and PI (10 μL), and incubated on ice in the dark for 15 minutes. Flow cytometric analysis was immediately conducted using an argon laser emitting at 488 nm using a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Data analysis was performed using the Summit V4.3 software (Beckman Coulter, Inc., Brea, CA, USA).

### Determination of DNA content of the cells by cell cycle analysis

Cell cycle analysis of ZER-NLC-treated leukemic cells was conducted according to the method described previously with slight modification.[@b15-ijn-10-1649] The WEHI-3B cells were seeded at a density 1×10^5^ cells/mL and incubated for 24 hours. The cells were then treated with 7.5±0.55 μg/mL ZER-NLC for 24 hours, 48 hours, and 72 hours. After incubation, the cell pellets were washed with the washing buffer (cold PBS/BSA/EDTA containing 0.1% sodium azide), fixed in 500 μL 80% cold ethanol, and kept at −20°C for 1 week. Then the cells were washed twice with washing buffer, and 1 mL staining buffer containing 0.1% Triton X-100, 50 μL RNase A (1.0 mg/mL), and 25 μL PI (1.0 mg/mL) was added to the fixed cells and incubated for 30 minutes on ice in the dark. The DNA content of cells was then analyzed using the BD FACSCalibur flow cytometer. Data analysis was performed using the Summit V4.3 software.

Caspase activities assay
------------------------

The caspase-3 and -9 activities in the WEHI-3B cells were determined using fluorometric assay kit according to the instructions of the manufacturer (Abcam, Cambridge, MA, USA). Briefly, 1×10^5^ WEHI-3B cells were seeded in a 96-well plate overnight, treated with 7.5±0.55 μg/mL ZER-NLC, and incubated for 24 hours, 48 hours, and 72 hours. The cells were then washed with cold PBS and made to a final volume of 50 μL with dH~2~O, and 5 μL active caspase, 50 μL master mix containing 2× reaction buffer, and 50 μM caspase substrate were added to the suspension. After incubation at 37°C for exactly 1 hour, the samples were read in a fluorescence plate reader (Infinite M200, Tecan, USA) equipped with a 400 nm excitation filter and 505 nm emission filter. Data were presented as OD, and a histogram was plotted.

In vivo antileukemic effect of ZER-loaded NLC
---------------------------------------------

### Preparation of cancer cells and leukemia induction

The WEHI-3B cells were grown to reach 90% confluence. The medium was removed, and the cells washed twice with PBS, stained with Trypan blue (Sigma-Aldrich), and counted under a light microscope (Nikon, Japan).[@b16-ijn-10-1649] The cells were then suspended in 300 μL PBS and used within 1 hour of preparation.

Animals
-------

Sixty adult male BALB/c mice aged 6 to 8 weeks were purchased from the animal house of the Faculty of Medicine, Universiti Putra Malaysia. The mice were housed in polypropylene plastic cages with wood chips as bedding. They were acclimatized to the laboratory environment at 24°C±1°C under a 12-hour dark--light cycle for at least 5 days before commencement of the experiment. The mice were provided pellet and water ad libitum during the period of study. This study was approved by the Animal Care and Use Committee (ACUC), Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM/FPV/PS/3.2.1.551/AUP-R152).

The mice were divided into six groups of ten animals each. All animals in five groups were anesthetized by intraperitonal injection of a mixture of ketamine·HCl and xylazine, and further injected intraperitonally with 300 μL of WEHI-3B cells (1×10^6^ cells/animal) in PBS using a tuberculin syringe and 26G needle. One group was not treated. Starting the following day, a drop of blood from the tail veins of four mice from each group was collected for 5 consecutive days. Blood smears were observed under Wright stain to ascertain development of leukemia.

Experimental design and drug treatment
--------------------------------------

Assignment of the mice groups was as follows: Group 1 comprised the untreated, normal, healthy mice and served as the negative controls. Group 2 served as the leukemia control, while Groups 3, 4, and 5 were leukemic mice treated daily with 60 mg/kg body weight with blank NLC (vehicle) and 30 and 60 mg/kg body weight ZER-NLC, respectively. Animals in Group 6 were treated with 4 mg/kg body weight all trans-retinoic acid (ATRA) (Sigma-Aldrich), an anticancer chemotherapy drug, dissolved in olive oil (Sigma-Aldrich) and served as positive control. The animals were deprived of feed for 12 hours prior to treatment. The drugs were given orally exactly 4 days after administration of WEHI-3B cells and after confirmation of leukemia development. Treatments were instituted through gastric intubations using a ball-tipped stainless steel gavage needle attached to a syringe, once every day for 4 consecutive weeks. At the end of the study, the mice were euthanized with an overdose of a mixture of ketamine·HCl and xylazine administered intraperitonally, and spleen samples were collected.

Histopathology
--------------

Spleen tissue samples were cut into small pieces and fixed in 10% formalin for at least 48 hours. The fixed samples were dehydrated using an automated tissue processor (Leica ASP300, Leipzig, Germany), embedded in paraffin wax (Leica EG1160, Leipzig, Germany). Then the blocks were trimmed and sectioned using a microtome (Leica RM2155). The tissue sections were mounted on glass slides using a hotplate (Leica HI1220) and subsequently treated in order with 100%, 90%, and 70% ethanol for 2 minutes each. Finally, the tissue sections were stained with the Harris's hematoxylin and eosin (H&E)[@b17-ijn-10-1649] and examined under a light microscope (Nikon, Chiyoda-ku, Tokyo, Japan) under ×1000 magnification.

Leukemia scoring was conducted on H&E-stained sections based on the number of leukemic cells in the spleen tissues. Score 0 = normal (no leukemic cells), score 1 = mild (leukemic cells between 0 cells/hpf and 25 cells/hpf), score 2 = moderate (leukemic cells between 25 cells/hpf and 50 cells/hpf), score 3 = severe (leukemic cells between 50 cells/hpf and 75 cells/hpf), and score 4 = more severe (leukemic cells between 75 cells/hpf and 100 cells/hpf).[@b18-ijn-10-1649]

Transmission electron microscopy
--------------------------------

Spleen samples were cut into sections of approximately 0.5 cm^2^ and fixed in 4% glutaraldehyde in a cocodylate buffer overnight. The specimens were washed in sodium cocodylate buffer and post-fixed in 1% osmium tetra-oxide. Then, the specimens were washed again in sodium cocodylate buffer, dehydrated in ascending grades (35%, 50%, 75%, 95%, and 100%) of acetone, infiltrated with a mixture of acetone and resin (50:50), embedded with 100% resin in beam capsule, and then polymerized. Then, the area of interest was chosen from the thick sections, stained with toulidine blue, and examined under light microscopy. The selected area was cut into ultrathin sections using an ultramicrotome, placed on copper grids, and stained with uranyl acetate and citrate. The tissue was finally washed twice with distilled water and viewed under a transmission electron microscope (Phillips, Eindhoven, the Netherlands).

TUNEL assay
-----------

Apoptosis in spleen tissues was determined using the TUNEL (Tdt-mediated dUTP nick-end labeling) kit according to manufacturer's protocol (DeadEnd™ fluorometric TUNEL system, Promega, Fitchburg, MI, USA). The spleen tissue sections were deparaffinized, rehydrated, fixed in formaldehyde, and equilibrated. Then, rTdT incubation buffer was added to the equilibrated area, which was then covered with a plastic cover slip and incubated at 37°C for 60 minutes in a humidified chamber away from direct light. The reactions were terminated by immersing the slides in 2× SSC (saline sodium citrate) and stained with freshly prepared PI solution in PBS in the dark. The slides were washed with PBS between each step. Finally, the samples were mounted on a glass cover slip and viewed under the fluorescent microscope using a standard fluorescent filter set to view the green fluorescence at 520±20 nm and the red fluorescence of PI at \>620 nm at ×400 magnification.

Apoptosis scoring of the TUNEL slides of the spleen tissue was based on the following: Score 0 = no apoptosis, score 1 = mild apoptosis (apoptotic cells between 0 cells/hpf and 25 cells/hpf), score 2 = moderate apoptosis (apoptotic cells between 25 cells/hpf and 50 cells/hpf), score 3 = highly moderated apoptosis (apoptotic cells between 50 cells/hpf and 75 cells/hpf), and score 4 = marked apoptosis (apoptotic cells between 75 cells/hpf and 100 cells/hpf).[@b19-ijn-10-1649]

Western blotting
----------------

Protein extraction from mice spleen tissues was done by snap-freezing the tissues in liquid nitrogen and adding RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) containing protease inhibitor cocktail (Sigma-Aldrich) to the tissue.[@b20-ijn-10-1649] The concentrations of protein in the suspensions were quantified using the Bradford protein assay kit.[@b21-ijn-10-1649] The suspension was aliquoted into PCR tubes (Bio-Rad Laboratories Inc., Hercules, CA, USA) and stored at −80°C until use. Equal amounts of protein (25 μg) were resolved and separated based on molecular weight via electrophoresis in an electric field of the 10% SDS-PAGE system (Bio-Rad). The broad, prestained protein molecular weight ladder (GeneDirex, Las Vegas, NV, USA) was used to assess protein migration. The proteins were transferred and blotted on to a polyvinylidene fluoride membrane (Bio-Rad) and were blocked sequentially for 1 hour in the blocking solution at room temperature on the Belly Dancer^®^ (Stovall, Life Science Inc., NC, USA). The membranes were washed with PBS containing 0.5% Tween-20 (PBST) and probed with specific primary antibodies to subunits *Bcl-2*, *Bax*, *Cyt-c*, *PARP*, and *FasL* in PBST containing 5% skimmed milk (Abcam, Cambridge, MA, USA), and mixed overnight at 4°C on a roller mixer. *β-Actin* served as the internal control.[@b22-ijn-10-1649] The following day, the membranes were washed several times with PBST and incubated with goat--anti-rabbit IgG conjugated to horseradish peroxidase secondary antibody in PBST containing 5% skimmed milk (Abcam, Cambridge, UK) at room temperature for 1 hour. The membranes were again washed with PBST. The immunoreacted protein bands were developed and detected using a chemiluminescence blotting substrate kit (ECL western blot substrate; Abcam, Cambridge, UK).[@b23-ijn-10-1649] A chemiluminescence image analyzer system (Chemi-Smart, Vilber Lourmat, Germany) was used to view the membranes. The results were expressed in standard units and intensity of bands was quantitated using the image J software (BioTechniques, New York, NY, USA).

Relative quantitative gene transcription assay (qRT-PCR)
--------------------------------------------------------

Total RNA was extracted from spleen tissue specimens using the RNeasy^®^ lipid tissue mini kit (Qiagen, Valencia, CA, USA)[@b24-ijn-10-1649] before conducting q-PCR analysis. The extracted RNA was quantified using a nanophotometer (IMPLEN, GmbH, Germany), aliquoted, and stored at −80°C. The sequences of the primers were designed by and obtained from Integrated DNA Technologies (IDT, Coralville, USA) ([Table S1](#SD1-ijn-10-1649){ref-type="supplementary-material"}). qRT-PCR assays for RNA of target *Bcl-2*, *Bax*, *Cyt-c*, *PARP*, and *FasL*, as well as the reference genes glyceraldehydes 3-phosphate dehydrogenase (*GAPDH*) and *β-actin*, were run for all animal groups using QIAGEN^®^ one-step RT-PCR SYBR green kit (Qiagen).[@b25-ijn-10-1649] The cycles were set at 50°C for 10 minutes (reverse transcription), 1 cycle of 95°C for 5 minutes (initial activation), and 39 cycles of 95°C for 10 seconds (denaturation) and 50°C--60°C for 30 seconds (combined annealing and extension). The fluorescence was recorded after each extension step. The threshold was set manually at the exponential phase of the amplification process, and the melting curve analysis was performed from 70°C to 95°C, with 0.5°C per 5-second increments. All reactions were performed in triplicates, and the relative expression of genes were analyzed using the CFX Manager™ software, version 1.6 (BioRad, Hercules, CA, USA) incorporated in the real-time PCR thermal cycler (BioRad). The Ct values were determined for each sample by comparing the values of the target gene with those of the *GAPDH* and *β-actin* constitutive gene products.

Statistical analysis
--------------------

The results were expressed as mean ± SD. Statistical analysis was accomplished using SPSS version 20.0. Data were analyzed using the one-way ANOVA, followed by the post hoc Tukey's *b*-test. Probability values of less than 0.05 (*P*\<0.05) were considered statistically significant.

Results and discussion
======================

The NLC-based drug-delivery systems are used for improving drug efficacy through increased solubility, sustained release, and prolonged effect and tissue targeting.[@b26-ijn-10-1649] This system is ideal for the water-insoluble ZER, facilitating parenteral applications, increasing the half-life, and improving tumor-targeted delivery.[@b27-ijn-10-1649] To ascertain the potential of ZER-NLC as an anticancer compound, its anticancer effects were determined by in vitro and in vivo methods.

In vitro cytotoxicity of ZER-NLC
--------------------------------

### Cell viability of WEHI-3B leukemia cells treated with ZER-NLC

Under the experimental conditions, various concentrations of ZER-NLC exhibited significant (*P*\<0.05) and marked inhibition on the survival of WEHI-3B cells with IC~50~ values 14.25±0.36 μg/mL, 10.42±0.77 μg/mL, and 7.5±0.55 μg/mL for 24 hours, 48 hours, and 72 hours treatment, respectively ([Figure 1A](#f1-ijn-10-1649){ref-type="fig"}). We have also shown in a previous study that the cytotoxicity of ZER-NLC is primarily due to the ZER itself and not NLC. In that study, we showed that the anticancer activity of ZER is not affected or impaired by its incorporation into NLC.[@b10-ijn-10-1649] In the current study, doxorubicin, an antitumor antibiotic made from natural products produced by the species of the soil fungus *Streptomyces*,[@b28-ijn-10-1649] was used as positive control. Doxorubicin imposed a significant (*P*\<0.05) cytotoxic effect on WEHI-3B cells in a time-dependent manner with an IC~50~ of 1.3±0.15 μg/mL, 1.09±1.24 μg/mL, and 0.82±1.5 μg/mL after 24 hours, 48 hours, and 72 hours incubation ([Figure 1B](#f1-ijn-10-1649){ref-type="fig"}). DMSO as a negative control did not exhibit any inhibitory effect toward WEHI-3B cells. By the IC~50~ values, ZER-NLC seems to exhibit lower cytotoxicity than doxorubicin on WEHI-3B cells.

### Induction of apoptosis achieved by Hoechst 33342 staining

In an attempt to elucidate the mechanism of loss in cell viability induced by ZER-NLC, the Hoechst 33342 staining technique was used to determine development of apoptosis and morphology of the treated WEHI-3B cells. Staining the ZER-NLC-treated WEHI-3B cells for 24 hours showed the development of typical features of apoptosis such as chromatin condensation and morphology changes, as well as cell shrinkage and membrane blebbing. The ZER-NLC-treated cells (48 hours) had smaller nuclei; some had peripherally condensed or clumped chromatin, whereas others had fragmented nuclear chromatin. Apoptotic body formation was more prominent at 72 hours post ZER-NLC treatment. These observations suggest that the death of ZER-NLC-treated WEHI-3B cells occurred in a time-dependent manner. In contrast, the cells in control group, which were not treated, demonstrated normal nuclear and cellular morphology ([Figure 2](#f2-ijn-10-1649){ref-type="fig"}).

### Phosphatidylserine externalization

The rate of apoptosis of ZER-NLC-treated WEHI-3B cells was quantitated using the Annexin V-FITC/PI staining method, which is based on the externalization of phosphatidylserine to the cell surface during apoptosis.[@b29-ijn-10-1649] The experiment showed that the population of early and late apoptotic cells increased gradually and significantly (*P*\<0.05) in all treated groups with a concomitant decrease in the viable cell population with time ([Figure 3](#f3-ijn-10-1649){ref-type="fig"}). At 12 hours of treatment, a large number of cells were primarily in the early phase of apoptosis (18.50%±0.91%) and, with increase in the incubation time to 48 hours and 72 hours, more cells entered the late phase of apoptosis with values of 19.79%±0.62% and 27.36%±0.10%, respectively ([Table S2](#SD2-ijn-10-1649){ref-type="supplementary-material"}).

Thus, we concluded that ZER-NLC treatment induces apoptosis in WEHI-3B cells in a time-dependent manner, with gradual and significant (*P*\<0.05) increase in early and late apoptotic cells and consequential decrease in viable cells. The results show that ZER-NLC induces suppression of WEHI-3B cell growth via induction of apoptosis.

### Cell cycle assay

Cell cycle analysis was conducted to verify the morphological changes, and the assessment by Annexin V/PI staining was to see the effect of ZER-NLC on apoptosis. In terms of cell cycle evaluation, shifts in the redistribution of cell cycle phases in response to various stimuli, including a response to growth factors, drugs, mutations, or nutrients, can be readily assessed by flow cytometry via the staining of DNA using dyes such as PI.[@b30-ijn-10-1649] Cell cycle analysis demonstrated that the untreated cells showed normal DNA content and cell cycle distribution. On the other hand, ZER-NLC induced significant (*P*\<0.05) accumulation of WEHI-3B cell population with a peak (21.22%±0.66%) at the subG0/G1 phase, especially after 72 hours of treatment. The result is consistent with the hypothesis that the appearance of sub-G1 cells is the marker of cell death by apoptosis.[@b31-ijn-10-1649] Treatment with ZER-NLC also induced cell cycle arrest in the G2/M phase with values of 10.54%±0.45%, 19.62%±0.37%, and 30.56%±0.53% after 24 hours, 48 hours, and 72 hours of treatment, respectively ([Figure 4](#f4-ijn-10-1649){ref-type="fig"} and [Table S3](#SD3-ijn-10-1649){ref-type="supplementary-material"}). Arrest of cancer cells in the G2/M phase induced by ZER-NLC was also shown to occur in the human lymphoblastic leukemia (Jurkat) cell line.[@b32-ijn-10-1649]

### Induction of apoptosis by caspase protease family

Caspases are produced by cells as inactive zymogens and undergo proteolytic activation during apoptosis. The activation of caspase proteases is a critical event in the induction of apoptosis.[@b33-ijn-10-1649] Caspase-9 is an upstream initiator caspase, while caspase-3 is one of the downstream effectors that play a central role in the initiation of apoptosis. Thus, to investigate the involvement of caspases in ZER-NLC-induced apoptosis, the activities of these proteases were determined in the treated WEHI-3B cells. ZER-NLC significantly (*P*\<0.05) stimulated both caspase-3 and -9 activities in the treated WEHI-3B cells with more than onefold time-dependent increase over the untreated control groups ([Figure 5](#f5-ijn-10-1649){ref-type="fig"} and [Table S4](#SD4-ijn-10-1649){ref-type="supplementary-material"}).

The mechanism of ZER-NLC-induced apoptosis in Jurkat and WEHI-3B cells is similar.[@b10-ijn-10-1649],[@b11-ijn-10-1649] Like in the case of Jurkat cells, ZER-NLC caused time-dependent increases in caspase-3 and -9 activities in WEHI-3B cells. Thus, these results suggest that ZER-NLC decreased the viability of WEHI-3B cells mainly through the induction of apoptosis via intrinsic mitochondrial pathway.

### In vivo antileukemic effect of ZER-NLC

The WEHI-3B leukemia cell line was first established in 1969 and demonstrated identifiable characteristics of myelomonocytic leukemia. It has since been used successfully to induce leukemia in syngenic BALB/c mice, which has become a useful animal model for leukemia studies, including the effect of drugs and natural compounds.[@b34-ijn-10-1649] In this study, the BALC/c mice were induced to develop leukemia with administration of WEHI-3B cells and treated with ZER-NLC.

Blood smear
-----------

Leukemic mice showed increased number of immature myeloid and monocytic cells in circulation. The cells appeared large with high cytoplasm to nucleus ratio ([Figure 6](#f6-ijn-10-1649){ref-type="fig"}). These manifestations were observed in the mice as early as 4 days following the intraperitonal inoculation of WEHI-3B cell line.

Histopathology
--------------

The spleen, as a secondary immune organ, with the high lymphocyte population, is the best organ to examine leukemia. Histopathologically, there was a massive and significant (*P*\<0.05) proliferation of pleomorphic neoplastic cells in the spleen parenchyma of untreated leukemic mice, which led to the disappearance of the sinusoids. These neoplastic cells were characterized by large, irregular nuclei with clumped chromatin. The same lesions with minor differences were also found in NLC-treated animals. On the other hand, the spleen tissues of mice treated with ZER-NLC or ATRA demonstrated significant reduction (*P*\<0.05) in leukemic cell population in comparison with the untreated normal control group ([Figure 7](#f7-ijn-10-1649){ref-type="fig"} and [Table S5](#SD5-ijn-10-1649){ref-type="supplementary-material"}). These findings are similar to those reported in previous BALB/c mice leukemia model studies.[@b12-ijn-10-1649],[@b35-ijn-10-1649]

Transmission electron microscopy
--------------------------------

TEM is a useful analytical tool in cell morphological studies in cancers. In this study, the spleen from untreated control mice showed normal cellular features. On the other hand, spleen from untreated leukemic mice showed pleomorphic cells, which were large in size, with markedly irregular surfaces and abnormal nuclear features. Treatment with ZER-NLC and ATRA produced apoptotic changes in the splenocytes characterized by margination of nuclear chromatin, nuclear lobulation, and cell membrane blebbing. Some apoptotic cells showed fragmented nucleus that formed apoptotic bodies ([Figure 8](#f8-ijn-10-1649){ref-type="fig"}).

TUNEL assay
-----------

Spleen tissue sections of leukemic mice treated with ZER-NLC and ATRA showed significant (*P*\<0.05) increase in the number of apoptotic cells as indicated by the high green fluorescence signal under microscopy. The spleen of untreated control and untreated leukemia groups showed nonsignificant (*P*\>0.05) apparent apoptosis. Spleen tissues of leukemic mice treated with NLC alone showed the presence of only a few apoptotic cells. Fragmentation of DNA resulting from the induction of apoptosis signaling pathway is usually associated with effects of anticancer agents. Using the TUNEL assay, we showed that ZER-NLC, like the anticancer drug ATRA, had antileukemia activity by inducing significant (*P*\<0.05) apoptosis of leukemic cells in the spleen of the BALB/c mice ([Figure 9](#f9-ijn-10-1649){ref-type="fig"} and [Table S6](#SD6-ijn-10-1649){ref-type="supplementary-material"}).

Western blotting analysis
-------------------------

The expression of pro- and anti-apoptotic proteins in cells treated with anticancer drugs is complementary to the data obtained from other molecular and morphological studies. Using western blotting analysis, it was shown that there is a significant (*P*\<0.05) increase in the expression of Bcl-2 protein in the splenocytes of leukemic and NLC-treated mice. The expression of Bax, Cyt-c, and PARP proteins was not significant (*P*\>0.05) in untreated and NLC-treated leukemic murine spleen. However, when the leukemic mice were treated with ZER-NLC and ATRA, the spleen showed significant (*P*\<0.05) increases in expression of *Bax*, *Cyt-c*, and PARP proteins, with significant (*P*\<0.05) suppression of the *Bcl-2* protein expression. Simultaneously, as a result of these treatments, the PARP protein cleaved from 116 kDa to 85 kDa in molecular weight. However, *FasL*, a type II transmembrane protein in the leukemic murine spleen, was not affected by the treatments ([Figures 10](#f10-ijn-10-1649){ref-type="fig"} and [11](#f11-ijn-10-1649){ref-type="fig"}; [Table S7](#SD7-ijn-10-1649){ref-type="supplementary-material"}). Thus the mode of anti-apoptotic effect of ZER-NLC is both by stimulating pro-apoptotic and inhibiting anti-apoptotic proteins.

Relative expression levels of gene transcripts using RT-qPCR
------------------------------------------------------------

RT-qPCR assay is considered the gold standard for gene expression analysis in various cells because of its reliability, accuracy, sensitivity, and fast quantification of results.[@b36-ijn-10-1649] This study is the first investigation on the mechanisms of the ZER-NLC-induced apoptosis in the WEHI-3B cells. Our study also determined gene transcription expression of some *Bcl-2* family members. It was found that the expression of the *Bcl-2* gene transcript was significantly (*P*\<0.05) upregulated in the leukemia control and the NLC-treated mice group, while that of *Bcl-2* was significantly (*P*\<0.05) downregulated in ZER-NLC- and ATRA-treated murine splenocytes. In case of *Bax*, *Cyt-c*, and *PARP*, their relative gene transcript expressions were significantly (*P*\>0.05) upregulated (*P*\<0.05) in the ZER-NLC- and ATRA-treated mice ([Figures 12](#f12-ijn-10-1649){ref-type="fig"} and [13](#f13-ijn-10-1649){ref-type="fig"}; [Table S8](#SD8-ijn-10-1649){ref-type="supplementary-material"}).

Collectively, the results of these experiments show that the changes of anti-apoptosis and pro-apoptosis *Bcl-2* family proteins are in a ratio that promotes apoptosis of leukemic cells, mediated primarily via an intrinsic mitochondrial pathway.[@b32-ijn-10-1649] Thus, this study unequivocally shows that ZER-NLC induces apoptosis of WEHI-3B cells through the mitochondrial-dependent pathway.

Conclusion
==========

In conclusion, this study confirmed that ZER-NLC induces apoptosis of leukemic cells. The apoptotic effect of ZER-NLC on mice myelomonocytic leukemia is similar to that in human T-lymphoblastic leukemia: that is, through the activation of mitochondrial pathway of apoptosis. This study is a verification of ZER-NLC as new drug-delivery system for the treatment of cancers.

Supplementary materials
=======================

###### 

Primer sequences in one-step SYBR green quantitative real-time PCR

  Primer      Forward sequence              Reverse sequence
  ----------- ----------------------------- -----------------------------
  *Bcl-2*     5′-CCAGACTCATTCAACCAGACA-3′   5′-GATGACTGAGTACCTGAACCG-3′
  *Bax*       5′-TTTGCTACAGGGTTTCAT-3′      5′-CTCCATATTGCTGTCCAG-3′
  *FasL*      5′-CTCCATATTGCTGTCCAGCG-3′    5′-TTTGCTACAGGGTTTCATGA-3′
  *Cyt-c*     5′-GTCTTATGCTTGCCTCCCTT-3′    5′-CGTCTGTCTTCGAGTCCGA-3′
  *PARP*      5′-CACCTCGTCACCTTTTCTCTT-3′   5′-GAGTACAGTGCCAGTCAGC-3′
  *β-Actin*   5′-CCAGACTCATTCAACCAGACA-3′   5′-GATGACTGAGTACCTGAACCG-3′
  *GAPDH*     5′-CGGGACCTAATGAAACTCCA-3′    5′-AATCTCCACTTTGCCACTGC-3′

###### 

Flow cytometric analysis of WEHI-3B cells treated with ZER-NLC

  Cell                      Cells (%)                                                                                                                                                   
  ------------------------- ------------ --------------------------------------------------------- ------------ ---------------------------------------------------------- ------------ ----------------------------------------------------------
  Viable cells              96.82±0.31   74.42±0.36                                                94.37±0.65   65.73±0.15                                                 93.92±0.25   55.06±0.35
  Early apoptosis           0.13±0.18    18.50±0.91[\*](#tfn2-ijn-10-1649){ref-type="table-fn"}    1.01±0.77    15.48±0.58[\*](#tfn2-ijn-10-1649){ref-type="table-fn"}     0.08±0.40    17.58±0.59[\*](#tfn2-ijn-10-1649){ref-type="table-fn"}
  Late apoptosis/necrosis   3.05±0.38    7.09±0.25[\*\*](#tfn3-ijn-10-1649){ref-type="table-fn"}   2.62±0.30    19.79±0.62[\*\*](#tfn3-ijn-10-1649){ref-type="table-fn"}   6.0±0.20     27.36±0.10[\*\*](#tfn3-ijn-10-1649){ref-type="table-fn"}

**Notes:** The cells were treated with ZER-NLC and incubated at 37°C for 12 hours, 24 hours, and 48 hours. Cells were stained with FITC-conjugated annexin V and PI, and analyzed by flow cytometry. Values are expressed as mean ± SD of three different experiments. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) increase in early apoptotic cells in ZER-NLC-treated groups in comparison with untreated controls.

Significant (*P*\<0.05) increase in late apoptotic/necrotic cells in ZER-NLC-treated groups in comparison with untreated control.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; FITC, fluorescein isothiocyanate; PI, propidium iodide; ANOVA, analysis of variance; h, hours; SD, standard deviation.

###### 

Flow cytometric analysis of WEHI-3B cells treated with ZER-NLC

  Cell cycle   Cells (%)                                                                                                                                                    
  ------------ ------------ ---------------------------------------------------------- ------------ ---------------------------------------------------------- ------------ ----------------------------------------------------------
  Sub-G0/G1    0.49±0.25    3.87±0.25[\*](#tfn6-ijn-10-1649){ref-type="table-fn"}      0.82±0.39    5.46±0.25[\*](#tfn6-ijn-10-1649){ref-type="table-fn"}      4.99±0.42    21.22±0.66[\*](#tfn6-ijn-10-1649){ref-type="table-fn"}
  G0/G1        50.79±0.26   59.74±0.55                                                 60.28±0.25   36.34±0.58                                                 69.54±0.39   41.34±0.60
  G2/M         6.75±0.75    10.58±0.45[\*\*](#tfn7-ijn-10-1649){ref-type="table-fn"}   11.26±0.20   19.22±0.37[\*\*](#tfn7-ijn-10-1649){ref-type="table-fn"}   9.66±0.28    30.56±0.53[\*\*](#tfn7-ijn-10-1649){ref-type="table-fn"}
  Synthesis    42.11±0.2    25.91±0.30                                                 27.62±0.56   39.03±0.15                                                 15.85±0.64   6.90±0.38

**Notes:** The cells were treated with ZER-NLC and incubated at 37°C for 24 hours, 48 hours, and 72 hours. Cells were stained with PI and analyzed by flow cytometry. Values are expressed as mean ± SD of three different experiments. Data have been analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) increase of cells in sub-G0/G1 phase in ZER-NLC-treated groups in comparison with untreated control.

Significant (*P*\<0.05) increase of cells in G2/M phase in ZER-NLC-treated groups in comparison with untreated controls.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; FITC, fluorescein isothiocyanate; PI, propidium iodide; ANOVA, analysis of variance; SD, standard deviation; h, hours.

###### 

Caspases fluorometric analysis of WEHI-3B cells after treated with ZER-NLC for 24 hours, 48 hours, and 72 hours

  Caspase     Cells (%)                                                                                                                                                
  ----------- ------------ ------------------------------------------------------- ------------ --------------------------------------------------------- ------------ --------------------------------------------------------
  Caspase-3   0.075±0.61   0.15±2.1[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}   0.089±0.31   0.10±0.45[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}    0.10±0.51    0.21±0.35[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}
  Caspase-9   0.082±0.54   0.18±0.3[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}   0.095±0.80   0.105±0.26[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}   0.105±0.83   0.225±1.4[\*](#tfn10-ijn-10-1649){ref-type="table-fn"}

**Notes:** Values are expressed as mean ± SD of three different experiments. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) increasing of apoptotic cells in ZER-NLC-treated groups in comparing to that of untreated control.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier ; ANOVA, analysis of variance; SD standard deviation; h, hours.

###### 

Histopathology lesion scoring for leukemic mice spleen tissues after stained with H&E staining

  Groups                Leukemic cells (%)                                          Non-leukemic cells (%)   Score   Degree
  --------------------- ----------------------------------------------------------- ------------------------ ------- -------------
  Control               0.0±0.0                                                     100.0±0.0                0       Normal
  Leukemia              81.5±1.38[\*](#tfn13-ijn-10-1649){ref-type="table-fn"}      18.49±0.61               4       More severe
  NLC                   68.17±1.1[\*](#tfn13-ijn-10-1649){ref-type="table-fn"}      31.83±1.2                4       More severe
  ZER-NLC (low dose)    20.45±0.65[\*\*](#tfn14-ijn-10-1649){ref-type="table-fn"}   79.55±0.65               1       Mild
  ZER-NLC (high dose)   18.2±0.72[\*\*](#tfn14-ijn-10-1649){ref-type="table-fn"}    81.8±0.12                1       Mild
  ATRA                  15.00±0.86[\*\*](#tfn14-ijn-10-1649){ref-type="table-fn"}   85.00±0.86               1       Mild

**Notes:** Values are expressed as mean ± SD. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) increase in leukemic cells in comparison with untreated controls.

Significant (*P*\<0.05) reduction in leukemic cells in comparison with untreated leukemia controls.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; ANOVA, analysis of variance; H&E, hematoxylin and eosin; SD, standard deviation; NLC, nanostructured lipid carrier.

###### 

Apoptotic lesion scoring for leukemic mice spleen tissues after stained with rTdT staining

  Groups                Apoptotic cells (%)                                      Non-apoptotic cells (%)   Score   Degree
  --------------------- -------------------------------------------------------- ------------------------- ------- -------------------
  Control               2.0±0.5                                                  98.67±0.5                 0       No apoptosis
  Leukemia              2.3±0.3                                                  97.5±0.3                  0       No apoptosis
  NLC                   5.3±0.8                                                  94.83±0.8                 0       No apoptosis
  ZER-NLC (low dose)    58.0±1.7[\*](#tfn17-ijn-10-1649){ref-type="table-fn"}    40.17±2.9                 4       Massive apoptosis
  ZER-NLC (high dose)   85.0±0.5[\*](#tfn17-ijn-10-1649){ref-type="table-fn"}    15.0±0.5                  4       Massive apoptosis
  ATRA                  93.00±1.5[\*](#tfn17-ijn-10-1649){ref-type="table-fn"}   7.00±0.86                 4       Massive apoptosis

**Notes:** Values are expressed as mean ± SD. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) increase in apoptotic cells in comparison with untreated controls.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; ANOVA, analysis of variance; SD, standard deviation; NLC, nanostructured lipid carrier.

###### 

Protein expression analysis in BALB/c mice spleen tissues via western blotting assay

  \% Protein expression level                                                                                                                                                                  
  ----------------------------- ------------ ------------ ------------ ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------
  *Bcl-2*                       22.34±0.02   45.00±1.7    42.01±0.55   30.33±0.12[\*](#tfn20-ijn-10-1649){ref-type="table-fn"}     27.12±0.35[\*](#tfn20-ijn-10-1649){ref-type="table-fn"}     23.45±3.0[\*](#tfn20-ijn-10-1649){ref-type="table-fn"}
  *Bax*                         20.90±0.13   14.56±1.5    18.46±0.54   38.32±0.25[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}   44.11±0.31[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}   58.21±1.5[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}
  *Cyt-c*                       15.32±0.19   12.30±0.19   15.70±0.29   24.98±0.8[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}    28.74±0.25[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}   32.77±1.7[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}
  *PARP*                        23.11±0.32   17.25±0.28   22.16±0.12   45.37±0.65[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}   48.67±0.75[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}   55.90±0.9[\*\*](#tfn21-ijn-10-1649){ref-type="table-fn"}
  *FasL*                        22.0±2.01    27.12±1.4    26.5±2.1     27.1±1.5                                                    26.8±0.55                                                   26.35±0.7

**Notes:** Values are expressed as mean ± SD. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) downregulation of protein in comparison with untreated leukemia controls.

Significant (*P*\<0.05) upregulation of protein in comparison with untreated leukemia controls.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; ANOVA, analysis of variance; SD, standard deviation; NLC, nanostructured lipid carrier.

###### 

Relative expression levels of *Bcl-2, Bax, Cyt-c, PARP*, and *FasL* normalized to the transcription levels of *β*-*actin* and *GAPDH* using one-step SYBR green qRT-PCR assay

  \% Gene expression level                                                                                                                                                                  
  -------------------------- ------------ ------------ ------------ ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------
  *Bcl-2*                    12.10±0.1    32.00±1.1    30.23±0.8    24.25±0.22[\*](#tfn24-ijn-10-1649){ref-type="table-fn"}     20.12±0.34[\*](#tfn24-ijn-10-1649){ref-type="table-fn"}     15.98±1.0[\*](#tfn24-ijn-10-1649){ref-type="table-fn"}
  *Bax*                      14.22±0.7    11.34±1.3    12.35±0.34   26.24±0.23[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}   32.10±0.37[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}   43.10±1.2[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}
  *Cyt-c*                    11.99±0.11   8.60±0.9     11.25±0.25   20.54±0.2[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}    27.43±0.45[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}   35.05±1.1[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}
  *PARP*                     16.43±0.3    13.13±0.08   11.15±0.15   25.12±0.41[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}   33.26±0.6[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}    40.09±0.5[\*\*](#tfn25-ijn-10-1649){ref-type="table-fn"}
  *FasL*                     22.11±0.15   26.7±0.25    25.23±0.64   23.5±1.2                                                    24.1±1.7                                                    25.45±2.01

**Notes:** Values are expressed as mean ± SD. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.

Significant (*P*\<0.05) downregulation of gene in comparison with untreated leukemia controls.

Significant (*P*\<0.05) upregulation of gene in comparison with untreated leukemia controls.

**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; ANOVA, analysis of variance; SD, standard deviation; NLC, nanostructured lipid carrier.
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![Cytotoxic effect of ZER-NLC (**A**) and doxorubicin (**B**) on WEHI-3B cells assessed by MTT assay.\
**Note:** Each point is the mean value of three replicates.\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; MTT, 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide; h, hours.](ijn-10-1649Fig1){#f1-ijn-10-1649}

![Fluorescent photomicrographs of WEHI-3B cells stained with Hoechst 33342 and treated with zerumbone nanostructured lipid carrier.\
**Notes:** (**A**) Control. (**B**) Chromatin condensation, membrane blebbing, and margination of the nucleus (24 hours). (**C**) Blebbing of cell membrane, chromatin condensation, marginated nucleus, and apoptotic body formation (48 hours). (**D**) Cell membrane blebbing, chromatin condensation, apoptosis body formation, cell shrinkage (×400 magnification), and death (72 hours).\
**Abbreviations:** BL, Blebbing; CC, chromatin condensation; MN, mariginated nucleus; AB, apoptotic body; CS, cell shrinkage.](ijn-10-1649Fig2){#f2-ijn-10-1649}

![Flow cytometric analysis of WEHI-3B cells treated with ZER-NLC and after staining with FITC-conjugated Annexin-V and PI.\
**Notes: A1**--**C1**: Untreated Jurkat cell control at 12 hours, 24 hours, and 48 hours, respectively. **A2**--**C2**: WEHI-3B cells treated with ZER-NLC for 12 hours, 24 hours, and 48 hours, respectively.\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; FITC, fluorescein isothiocyanate; PI, propidium iodide.](ijn-10-1649Fig3){#f3-ijn-10-1649}

![Cell cycle analysis of WEHI cells treated with zerumbone nanostructured lipid carrier.\
**Notes:** The DNA contents were analyzed by flow cytometry. **A1**--**C1**: Untreated WEHI-3B cell control at 24 hours, 48 hours, and 72 hours, respectively. **A2**--**C2**: WEHI-3B cells treated with zerumbone nanostructured lipid carrier for 24 hours, 48 hours, and 72 hours, respectively. G0/G1, G2/M, and S are cell phases, and sub-G1 DNA content refers to apoptotic cells.](ijn-10-1649Fig4){#f4-ijn-10-1649}

![Effect of ZER-NLC on caspase-3 and -9 activities in the WEHI-3B cells after 24 hours, 48 hours, and 72 hours of treatment.\
**Notes:** Results are expressed as the optical density (400 nm) ± SD of three independent experiments. \*Indicates a significant difference (*P*\<0.05).\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; h, hours; SD, standard deviation.](ijn-10-1649Fig5){#f5-ijn-10-1649}

![Peripheral blood myeloid (red arrow) and monocytic (black arrow) cells in leukemic BALB/c mice (×1000 magnification).](ijn-10-1649Fig6){#f6-ijn-10-1649}

![Spleen of BALB/c mice (H&E).\
**Notes:** (**A**) Untreated control representing normal cells. (**B**) Leukemia control representing massive neoplastic cells. (**C**) Nanostructured lipid-carrier-treated group representing distinctive neoplastic cells. (**D**) Low-dose zerumbone nanostructured lipid-carrier-treated group demonstrating the reduction in the number of leukemic cells. (**E**) High-dose zerumbone nanostructured lipid-carrier-treated and (**F**) ATRA-treated groups representing high reduction in leukemic cells in comparison to leukemia control. Normal cells are represented by white arrows and leukemic cells by black arrows (×1000 magnification).\
**Abbreviations:** ATRA, all trans-retinoic acid; H&E, hematoxylin and eosin.](ijn-10-1649Fig7){#f7-ijn-10-1649}

![Ultrastructure of spleen tissue of BALB/c mice.\
**Notes:** (**A**) Normal cell of untreated control group. (**B**) Giant leukemic cell in untreated leukemic mice. (**C**) Nanostructure lipid-carrier-treated group showing neoplastic cell. (**D**) Low-dose zerumbone-loaded nanostructure lipid-carrier-treated spleen showing blebbing, condensation, and margination of nucleus. (**E**) High-dose zerumbone-loaded nanostructure lipid-carrier-treated spleen showing blebbing, nuclear fragmentation, and chromatin condensation. (**F**) ATRA-treated spleen showing nuclear fragmentation and chromatin condensation.\
**Abbreviation:** ATRA, all trans-retinoic acid.](ijn-10-1649Fig8){#f8-ijn-10-1649}

![Spleen tissue of BALB/c mice analyzed by TUNEL assay.\
**Notes:** (**A**) Untreated normal control. (**B**) Leukemic group. Both groups show non-apoptotic cells. (**C**) Nanostructured lipid carrier-treated spleen showing nonsignificant (*P*\>0.05) apoptosis. (**D**) Low-dose zerumbone-loaded nanostructured-lipid-carrier treated spleen showing significant apoptosis (*P*\<0.05). (**E**) High-dose zerumbone-loaded nanostructured lipid-carrier-treated spleen showing significant apoptosis (*P*\<0.05), (**F**) ATRA-treated spleen tissue. Both treatments caused significant (*P*\<0.05) increase in number of apoptotic cells. Non-apoptotic cells: orange colored (white arrows); apoptotic cells: fluorescent colored (black arrows) (×400 magnification).\
**Abbreviations:** TUNEL, Tdt-mediated dUTP nick-end labeling; ATRA, all trans-retinoic acid.](ijn-10-1649Fig9){#f9-ijn-10-1649}

![Protein expression in spleen tissue of leukemic BALB/c mice observed by western blotting assay.\
**Notes:** (**A**) Untreated control. (**B**) Leukemia control. (**C**) Nanostructured lipid-carrier-treated (NLC) tissue. (**D**) Low-dose zerumbone-loaded nanostructured lipid carrier treated tissue. (**E**) High-dose zerumbone-loaded nanostructured lipid carrier treated tissue. (**F**) ATRA-treated tissue.\
**Abbreviation:** ATRA, all trans-retinoic acid.](ijn-10-1649Fig10){#f10-ijn-10-1649}

![Protein expression analysis in BALB/c mice spleen tissues by western blotting assay using Image J software.\
**Notes:** Data have been analyzed using post hoc comparison test/one-way ANOVA, means compare by Tukey's *b*-test. Data revealed significant (*P*\<0.05) expression of *Bax*, *Cyt-c*, and *PARP* proteins in treated (ZER-NLC and ATRA) groups compared to the untreated leukemia control group. However, significant suppression (*P*\<0.05) of *Bcl-2* protein was found in treated (ZER-NLC and ATRA) groups compared to untreated leukemic group. Nonsignificant expression (*P*\>0.05) of *FasL* protein was found in ZER-NLC- and ATRA-treated groups.\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; ANOVA, analysis of variance.](ijn-10-1649Fig11){#f11-ijn-10-1649}

![The amplification plot of *β-actin* (**A**), *GAPDH* (**B**), *Bcl-2* (**C**), *Bax* (**D**), *Cyt-c* (**E**), *PARP* (**F**), and *FasL* (**G**) genes.\
**Notes:** qPCR analysis was performed on leukemic BALB/c spleen tissue treated with different doses of ZER-NLC and ATRA using CFX Manager™ software (version 1.6; BioRad, Hercules, CA, USA).\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; qPCR, quantitative polymerase chain reaction; RFU, relative fluorescence unit.](ijn-10-1649Fig12){#f12-ijn-10-1649}

![mRNA expression quantity levels of *Bcl-2, Bax, Cyt-c, PARP,* and *FasL* normalized to the transcription levels of *β-actin* and *GAPDH*. qPCR analysis was performed on leukemic BALB/c spleen tissue treated with different doses of ZER-NLC and ATRA. Values are expressed as mean ± SD. Data were analyzed using post hoc comparison test one-way ANOVA, and means compared by Tukey's *b*-test.\
**Abbreviations:** ZER-NLC, zerumbone-loaded nanostructured lipid carrier; ATRA, all trans-retinoic acid; qPCR, quantitative polymerase chain reaction; ANOVA, analysis of variance; SD, standard deviation.](ijn-10-1649Fig13){#f13-ijn-10-1649}
